. mRNA expression data are altered in 212/489 (43%) sequenced patient tumors. Data were obtained from the Ovarian Serous Cystadenocarcinoma (The Cancer Genome Atlas) dataset in cBioPortal. DLL3, Delta-like protein 3; MAML1, Mastermind-like protein 1; ADAM17, a disintegrin and metalloproteinase 17.
. mRNA expression levels of NOTCH1 and NOTCH4 in normal ovaries and corresponding ovarian cancer tissues. Data were obtained from Gene Expression across Normal and Tumor tissue (GENT). Ovary-N, normal ovaries; Ovary-C, ovarian cancer. Figure S3 . Survival and cancer grade association data for (A-C) NOTCH1, (D-F) NOTCH4 and (G-I) MAML2. Data were obtained from CSIOVDB. MAML2, Mastermind-like protein 2; Q, quartile. The red text for the plot titles suggested high levels of the genes were generally associated with poor survival or advanced cancer stages, while the green text indicated association with either good survival/early cancer stages or no clear trend. 4.21x10
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High levels of the genes were generally associated with advanced cancer stages; b association with early stages or no clear trend. DLL, Delta-like protein; MAML, Mastermind-like protein; ADAM17, a disintegrin and metalloproteinase 17; NCSTN, nicastrin. Rest indicate the rest of the stages. We mainly focused on the comparison between advanced cancer stages (stages III and IV) and early stage I. Only individual tests with P<0.005 were considered to be significant; these are highlighted in bold. Table SIV . Survival data for the 50 most frequently altered neighboring genes involved with the NOTCH2/ NOTCH3/DLL3/MAML1/ADAM17 network. Datasets were analyzed using the CSIOVDB.
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